Mutatis mutandis: Harmonize the standard!

Journal of Nuclear Medicine

Volumn 53, Issue 1, 2012, Pages 1-3

  Boellaard, Ronald ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ANALYTICAL PARAMETERS; COMPUTER ASSISTED TOMOGRAPHY; HEALTH CARE PRACTICE; HUMAN; IMAGE ANALYSIS; IMAGING SYSTEM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIOLOGICAL PARAMETERS; SHORT SURVEY; STANDARDIZATION; STANDARDIZED UPTAKE VALUE;

BIOLOGICAL TRANSPORT; HUMANS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; REFERENCE STANDARDS;

EID: 84855408644     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.094763     Document Type: Short Survey

References (17)

1. Hunter AJ. The Innovative Medicines Initiative: a pre-competitive initiative to enhance the biomedical science base of Europe to expedite the development of new medicines for patients. Drug Discov Today. 2008;13:371-373.
2. Woosley RL, Myers RT, Goodsaid F. The Critical Path Institute's approach to precompetitive sharing and advancing regulatory science. Clin Pharmacol Ther. 2010;87:530-533.
3. 18F-FDG PET in oncology. J Nucl Med. 2008;49:480-508.
4. de Geus-Oei LF, van der Heijden HF, Corstens FH, Oyen WJ. Predictive and prognostic value of FDGPET in nonsmall-cell lung cancer: a systematic review. Cancer. 2007;110:1654-1664. (Pubitemid 47557290)
5. 18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment. Lung Cancer. 2003;39:151-157.
6. Weber WA. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med. 2005;46:983-995. (Pubitemid 43733514)
7. Stahl A, Ott K, Schwaiger M, Weber WA. Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET. Eur J Nucl Med Mol Imaging. 2004;31:1471-1478.
8. 18F]FDG PET imaging parameters on automatic tumour delineation: need for improved tumour delineation methodology. Eur J Nucl Med Mol Imaging. 2011.
9. Boellaard R, Krak NC, Hoekstra OS, Lammertsma AA. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med. 2004;45:1519-1527. (Pubitemid 47618506)
10. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(suppl 1):122S-150S.
11. Makris NE, Huisman MC, Lammertsma AA, Boellaard R. Comparison of scanner validation programs used in oncology FDG PET/CT trials: impact of image reconstruction settings and VOI definition method [abstract]. Eur J Nucl Med Mol Imaging. 2011;38(suppl 2):S172.
12. Vanderhoek M, Perlman SB, Jeraj R. Impact of the definition of peak standardized uptake value on quantification of treatment response [abstract]. J Nucl Med. 2012;53:4-11.
13. Boellaard R. Standards for PET image acquisition and quantitative data analysis. J Nucl Med. 2009; 50(suppl 1):11S-20S.
14. 18F-FDG PET as an indicator of therapeutic response in patients in national cancer institute trials. J Nucl Med. 2006;47:1059-1066.
15. Yap J, Locascio T, Tanaka Y, Syrkin L, Van Den Abbeele A. Impact of variations in SUV methods for assessing cancer response using FDG-PET [abstract]. J Nucl Med. 2011;52(suppl 1):392P.
16. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35:1773-1782.
17. Metre. Wikipedia: The Free Encyclopedia. Available at: http://en.wikipedia.org/wiki/Meter. Accessed November 22, 2011.